MX2021000397A - Moleculas de union a mesotelina y cd137. - Google Patents

Moleculas de union a mesotelina y cd137.

Info

Publication number
MX2021000397A
MX2021000397A MX2021000397A MX2021000397A MX2021000397A MX 2021000397 A MX2021000397 A MX 2021000397A MX 2021000397 A MX2021000397 A MX 2021000397A MX 2021000397 A MX2021000397 A MX 2021000397A MX 2021000397 A MX2021000397 A MX 2021000397A
Authority
MX
Mexico
Prior art keywords
mesothelin
binding molecules
antibody molecules
msln
binding site
Prior art date
Application number
MX2021000397A
Other languages
English (en)
Inventor
Mihriban Tuna
Jose Munoz-Olaya
Francisca Wollerton
Remi Fertin
Claire Reader
Neil Brewis
Original Assignee
F Star Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Therapeutics Ltd filed Critical F Star Therapeutics Ltd
Publication of MX2021000397A publication Critical patent/MX2021000397A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a moléculas de anticuerpo que se unen tanto a mesotelina (MSLN) como a CD137. Las moléculas de anticuerpo comprenden un sitio de unión basado en CDR para MSLN, y un sitio de unión al antígeno CD137 ubicado en un dominio constante de la molécula de anticuerpo. Las moléculas de anticuerpo encuentran aplicación en el tratamiento del cáncer, por ejemplo.
MX2021000397A 2018-07-12 2019-07-12 Moleculas de union a mesotelina y cd137. MX2021000397A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1811450.4A GB201811450D0 (en) 2018-07-12 2018-07-12 Mesothelin and CD137 binding molecules
PCT/EP2019/068817 WO2020011976A1 (en) 2018-07-12 2019-07-12 Mesothelin and cd137 binding molecules

Publications (1)

Publication Number Publication Date
MX2021000397A true MX2021000397A (es) 2021-05-27

Family

ID=63273224

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000397A MX2021000397A (es) 2018-07-12 2019-07-12 Moleculas de union a mesotelina y cd137.

Country Status (14)

Country Link
US (1) US20210309753A1 (es)
EP (1) EP3820894A1 (es)
JP (2) JP7360441B2 (es)
KR (1) KR20210030925A (es)
CN (1) CN112437776A (es)
AR (1) AR115769A1 (es)
AU (1) AU2019303081A1 (es)
BR (1) BR112021000396A2 (es)
CA (1) CA3103173A1 (es)
GB (1) GB201811450D0 (es)
IL (1) IL280007A (es)
MX (1) MX2021000397A (es)
SG (1) SG11202011960XA (es)
WO (1) WO2020011976A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CA3086098A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Fc binding fragments comprising a pd-l1 antigen-binding site
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
WO2024039672A2 (en) * 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024042105A1 (en) 2022-08-26 2024-02-29 Merck Patent Gmbh Cancer treatment comprising an anti-msln/cd137 antibody and a chemotherapeutic
WO2024042104A1 (en) 2022-08-26 2024-02-29 Merck Patent Gmbh Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE60039510D1 (de) 1999-05-27 2008-08-28 Us Gov Health & Human Serv Immunokonjugate mit hoher bindungsaffinität
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN101098891B (zh) 2005-01-05 2014-05-21 F-星生物技术研究与开发有限公司 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
PL2215121T3 (pl) 2007-11-26 2016-07-29 Bayer Ip Gmbh Przeciwciała przeciwko mezotelinie i ich zastosowania
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
AU2013324049B2 (en) * 2012-09-27 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
KR101782487B1 (ko) * 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물
KR102426765B1 (ko) * 2016-04-22 2022-07-29 엘리게이터 바이오사이언스 에이비 Cd137에 대한 신규한 이중특이성 폴리펩타이드
AU2017271601A1 (en) 2016-05-27 2018-12-13 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
CN107523546A (zh) * 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的nk细胞及其用途

Also Published As

Publication number Publication date
JP7360441B2 (ja) 2023-10-12
GB201811450D0 (en) 2018-08-29
KR20210030925A (ko) 2021-03-18
IL280007A (en) 2021-03-01
CN112437776A (zh) 2021-03-02
EP3820894A1 (en) 2021-05-19
AR115769A1 (es) 2021-02-24
CA3103173A1 (en) 2020-01-16
SG11202011960XA (en) 2020-12-30
JP2023178323A (ja) 2023-12-14
BR112021000396A2 (pt) 2021-04-06
US20210309753A1 (en) 2021-10-07
WO2020011976A1 (en) 2020-01-16
TW202012448A (zh) 2020-04-01
AU2019303081A1 (en) 2021-03-11
JP2021524269A (ja) 2021-09-13

Similar Documents

Publication Publication Date Title
MX2021000397A (es) Moleculas de union a mesotelina y cd137.
MX2019009967A (es) Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
MX2021000399A (es) Moleculas de anticuerpo que se unen a cd137 y ox40.
MX2021000398A (es) Moleculas de anticuerpo que se unen a pd-l1 y cd137.
MX2018010948A (es) INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
MX2018016320A (es) Moleculas de union que se unen a (pd-l1) y (lag-3).
MX2022014463A (es) Construcciones de union a antigeno para moleculas diana.
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
CR20200467A (es) Agentes anticuerpos anti-cd25
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
TN2019000272A1 (en) Anti-ilt4 antibodies and antigen-binding fragments.
BR112017027254A2 (pt) anticorpos anti-cd123 e conjugados e derivados dos mesmos
PH12021550662A1 (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MX2021000392A (es) Anticuerpos anti-mesotelina.
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
EA202191893A1 (ru) Молекулы, связывающие рецептор трансферрина, их конъюгаты и их применение
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
MX2021000387A (es) Fragmentos de union a fc que comprenden un sitio de union al antigeno cd137.
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
MY192146A (en) Binding molecules specific for asct2 and uses thereof
MX2022005717A (es) Moleculas de anticuerpos anti-siglec-9.